<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Triamterene nephrotoxicity
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Triamterene nephrotoxicity
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Triamterene nephrotoxicity
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Gary C Curhan, MD, ScD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 09, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          Triamterene
         </a>
         is a potassium-sparing diuretic that is commonly used in the treatment of hypertension in combination with a thiazide diuretic. It is not widely appreciated, however, that triamterene is a potential nephrotoxin, occasionally inducing crystalluria and cast formation, and rarely causing stone formation or reversible acute kidney injury [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The evaluation, diagnosis, and acute management of kidney stones and the general management of acute kidney injury in adults is discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7366.html" rel="external">
          "Kidney stones in adults: Diagnosis and acute management of suspected nephrolithiasis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14035.html" rel="external">
          "Overview of the management of acute kidney injury (AKI) in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CRYSTALLURIA AND CAST FORMATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          Triamterene
         </a>
         can induce the formation of both triamterene crystals (which are usually brown in color, spherical, and appear as a "Maltese cross" under polarized light) and granular casts (which can look identical to brown pigmented casts), at least when used in higher doses (eg, 50 to 100 mg daily). The following studies illustrate this effect:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 20 healthy adults who ingested 100 mg of
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         , all 20 excreted triamterene crystals, and 17 out of 20 excreted granular casts, which were present within 11 hours of taking the drug [
         <a href="#rid3">
          3
         </a>
         ]. Alkalinization of the urine to a pH of 7.5 or higher prevented the appearance of crystals.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study of 26 hypertensive patients given 50 mg of
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         , crystals and casts were seen in 14 (54 percent) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Whether crystals and casts commonly occur with 37.5 mg of
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         (a more typical dose) is unknown. The mechanism responsible for the cast formation is unclear but appears to be specific to triamterene, as this finding is not seen with
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          amiloride
         </a>
         , another potassium-sparing diuretic [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          TRIAMTERENE STONES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stone formation is an uncommon complication of
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         therapy [
         <a href="#rid2">
          2,5-7
         </a>
         ]. One study, for example, found that triamterene was present in 1 in every 200 to 250 stones [
         <a href="#rid6">
          6,8
         </a>
         ]. Most of these stones contained both triamterene and calcium oxalate or uric acid, although pure triamterene stones did occur [
         <a href="#rid6">
          6,9
         </a>
         ]. Of course, the proportion of all stones containing triamterene will depend upon how commonly triamterene is used in the general population. In addition, the incidence of triamterene-containing stones may be decreasing [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Patients who form triamterene-containing stones are more likely to have a prior history of stone disease, suggesting that metabolic predisposition is an important risk factor [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7375.html" rel="external">
          "Kidney stones in adults: Epidemiology and risk factors"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          Triamterene
         </a>
         stones are faintly opaque on radiograph examination and, like other stones, are easily seen with non-contrasted computed tomography. (See
         <a class="medical medical_review" href="/z/d/html/7366.html" rel="external">
          "Kidney stones in adults: Diagnosis and acute management of suspected nephrolithiasis", section on 'Diagnostic imaging'
         </a>
         .)
        </p>
        <p>
         Early studies suggested no relation with urine pH, but later studies found that
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         crystals are not seen when the urine pH is 7.5 or higher. If triamterene crystals are seen, the medication should be stopped.
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          Amiloride
         </a>
         is an alternative potassium-sparing agent that does not form crystals in the urine.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          Triamterene
         </a>
         stones cannot be dissolved by raising the urine pH and should be treated by conventional urologic techniques [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7371.html" rel="external">
          "Kidney stones in adults: Surgical management of kidney and ureteral stones"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          ACUTE KIDNEY INJURY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reversible acute kidney injury is another rare problem with
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         (but not other potassium-sparing diuretics). Two different mechanisms have been described: intratubular obstruction by crystals and concurrent therapy with a nonsteroidal antiinflammatory drug (NSAID) [
         <a href="#rid12">
          12-14
         </a>
         ]. Why triamterene seems to make the patient more sensitive to NSAIDs than other diuretics is not clear. (See
         <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">
          "NSAIDs: Acute kidney injury"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20367461">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          Triamterene
         </a>
         , a commonly used potassium-sparing diuretic, may produce crystalluria and granular casts in as many as one-half of patients taking higher doses, sometimes leading to nephrolithiasis or acute kidney injury. The risk with the more typical dose of 37.5 mg of triamterene is unknown.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients taking
         <a class="drug drug_general" data-topicid="10016" href="/z/d/drug information/10016.html" rel="external">
          triamterene
         </a>
         , the medication should be discontinued if crystals or casts are seen in the urine or if triamterene is reported as a component of a stone.
         <a class="drug drug_general" data-topicid="8550" href="/z/d/drug information/8550.html" rel="external">
          Amiloride
         </a>
         is a safe alternative.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sica DA, Gehr TW. Triamterene and the kidney. Nephron 1989; 51:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perazella MA. Crystal-induced acute renal failure. Am J Med 1999; 106:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fairley KF, Woo KT, Birch DF, et al. Triamterene-induced crystalluria and cylinduria: clinical and experimental studies. Clin Nephrol 1986; 26:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spence JD, Wong DG, Lindsay RM. Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide. Lancet 1985; 2:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woolfson RG, Mansell MA. Does triamterene cause renal calculi? BMJ 1991; 303:1217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr MC, Prien EL Jr, Babayan RK. Triamterene nephrolithiasis: renewed attention is warranted. J Urol 1990; 144:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabot JF, Bornet CE, Favre S, Sabot-Gueriaux S. The analysis of peculiar urinary (and other) calculi: an endless source of challenge. Clin Chim Acta 1999; 283:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ettinger B, Oldroyd NO, Sörgel F. Triamterene nephrolithiasis. JAMA 1980; 244:2443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sörgel F, Ettinger B, Benet LZ. The true composition of kidney stones passed during triamterene therapy. J Urol 1985; 134:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daudon M, Jungers P. Drug-induced renal calculi: epidemiology, prevention and management. Drugs 2004; 64:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matlaga BR, Shah OD, Assimos DG. Drug-induced urinary calculi. Rev Urol 2003; 5:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med 1982; 96:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinberg MS, Quigg RJ, Salant DJ, Bernard DB. Anuric renal failure precipitated by indomethacin and triamterene. Nephron 1985; 40:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasr SH, Milliner DS, Wooldridge TD, Sethi S. Triamterene crystalline nephropathy. Am J Kidney Dis 2014; 63:148.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7365 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2662034" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Triamterene and the kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10225250" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Crystal-induced acute renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3780069" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Triamterene-induced crystalluria and cylinduria: clinical and experimental studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2861527" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effects of triamterene and amiloride on urinary sediment in hypertensive patients taking hydrochlorothiazide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1747638" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Does triamterene cause renal calculi?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2231920" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Triamterene nephrolithiasis: renewed attention is warranted.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10404739" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The analysis of peculiar urinary (and other) calculi: an endless source of challenge.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7431573" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Triamterene nephrolithiasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4057369" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The true composition of kidney stones passed during triamterene therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14871169" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Drug-induced renal calculi: epidemiology, prevention and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16985842" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Drug-induced urinary calculi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6949485" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4000350" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Anuric renal failure precipitated by indomethacin and triamterene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23958399" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Triamterene crystalline nephropathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
